Status:
UNKNOWN
Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema
Lead Sponsor:
University of Sao Paulo
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Diabetic Retinopathy
Macular Edema
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular...
Eligibility Criteria
Inclusion
- Center-involving Diabetic macular edema unresponsive to LASER therapy performed at least 3 moths prior to inclusion;
- Best corrected visual acuity equal or worse than 20/40 and better than 20/800;
- Central subfield macular thickness greater than 300 µm
Exclusion
- Aphakia
- High-risk proliferative diabetic retinopathy
- Previous treatment for DME in the past three months
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT01487629
Start Date
April 1 2010
End Date
September 1 2012
Last Update
December 13 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinics Hospital of Ribeirão Preto, School of Medicine of Ribeirão Preto, USP
Ribeirão Preto, São Paulo, Brazil, 14048-900